6-month course of antiandrogen drugs
2023-SR-258
Phase 3 small_molecule active
Quick answer
6-month course of antiandrogen drugs for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) is a Phase 3 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active